The storm has cleared: Lessons from the CD28 superagonist TGN1412 trial

Nature Reviews Immunology

Volumn 12, Issue 5, 2012, Pages 317-318

  Hünig, Thomas ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; GAMMA INTERFERON; GLUCOCORTICOID; INTERLEUKIN 2; OKT 3; T LYMPHOCYTE RECEPTOR; TGN 1412; TUMOR NECROSIS FACTOR;

ANTIGEN RECOGNITION; CD4+ T LYMPHOCYTE; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; CYTOKINE RELEASE SYNDROME; EFFECTOR CELL; HUMAN; INTENSIVE CARE; MEMORY CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; IMMUNOMODULATION; LEUKOCYTES, MONONUCLEAR; MALE; YOUNG ADULT;

EID: 84860257860     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3192     Document Type: Review

References (15)

1. Suntharalingam, G. et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018-1028 (2006). (Pubitemid 44343545)
2. Tacke, M., Hanke, G., Hanke, T. & Hunig, T. CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: evidence for functionally distinct forms of CD28. Eur. J. Immunol. 27, 239-247 (1997). (Pubitemid 27046084)
3. Dennehy, K. M. et al. Mitogenic CD28 signals require the exchange factor Vav1 to enhance TCR signaling at the SLP-76-Vav-Itk signalosome. J. Immunol. 178, 1363-1371 (2007). (Pubitemid 46154606)
4. Levin, S. E., Zhang, C., Kadlecek, T. A., Shokat, K. M. & Weiss, A. Inhibition of ZAP-70 kinase activity via an analog-sensitive allele blocks T cell receptor and CD28 superagonist signaling. J. Biol. Chem. 283, 15419-15430 (2008).
5. Lin, C.-H. & Hunig, T. Efficient expansion of regulatory T-cells in vitro and in vivo with a CD28 superagonist. Eur. J. Immunol. 33, 626-638 (2003). (Pubitemid 36367666)
6. Hunig, T. Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies. Adv. Immunol. 95, 111-148 (2007). (Pubitemid 47380504)
7. Gogishvili, T. et al. Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice. PLoS ONE 4, e4643 (2009).
8. Eastwood, D. et al. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br. J. Pharmacol. 161, 512-526 (2010).
9. Römer, P. S. et al. Preculture of PBMC at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Blood 118, 6772-6782 (2011).
10. Beyersdorf, N. et al. Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J. Exp. Med. 202, 445-455 (2005). (Pubitemid 41126962)
11. Hanke, T. Lessons from TGN1412. Lancet 368, 1569-1570; author reply 1570 (2006). (Pubitemid 44691903)
12. Abramowicz, D. et al. Release of tumor necrosis factor, interleukin-2, and γ-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 47, 606-608 (1989). (Pubitemid 19110914)
13. Stefanova, I., Dorfman, J. R. & Germain, R. N. Self-recognition promotes the foreign antigen sensitivity of naive T lymphocytes. Nature 420, 429-434 (2002). (Pubitemid 35415655)
14. Duff, G. W. et al. Expert Scientific Group on Phase One Clinical Trials: Final Report (Stationary Office, Norwich, UK, 2006).
15. Waibler, Z. et al. Toward experimental assessment of receptor occupancy: TGN1412 revisited. J. Allergy Clin. Immunol. 122, 890-892 (2008).